20-carbon-sphingosine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 20-carbon-sphingosine
• 英文别名: (E,2R,3S)-2-aminoicos-4-ene-1,3-diol
• 化学式: C₂₀H₄₁NO₂
• 分子量: 327.551
• InChiKey: HTJSZHKGNMXZJN-QWKHPXNBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  23
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  66.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  20-carbon-sphingosine 、 维A酸 在 4-二甲氨基吡啶 、 N,N'-二异丙基碳二亚胺 作用下， 以 N-甲基吡咯烷酮 、 四氢呋喃 为溶剂， 生成
  参考文献：
  名称：

  The Synthesis and Biological Characterization of a Ceramide Library

  摘要：

  A facile synthesis of a combinatorial ceramide library and their activities in the NF-kappaB pathway and in apoptosis induction/prevention were demonstrated. A novel NF-kappaB activating molecule was discovered among ceramide containing beta-galactose, and the structural requirements of ceramides for apoptosis induction was elucidated.

  DOI：

  10.1021/ja017576o

文献信息

• Mutant endoglycoceramidases with enhanced synthetic activity
  申请人：La Jolla Pharmaceutical Company

  公开号：US10294504B2

  公开（公告）日：2019-05-21

  The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.

  本发明涉及一种新型内聚甘糖苷酶，其水解活性已大大降低或消除，因此该酶可用于由单糖或寡糖和神经酰胺合成糖脂。更具体地说，内糖化酶是天然存在的内糖化酶的突变体，优选包括酶的活性位点或亲核位点内的突变，更优选包括活性位点或亲核位点内 Glu 残基的取代突变。还公开了一种产生突变型内糖化酶的方法和一种使用这种突变型酶酶解合成糖脂的方法。
• Sphingoid compounds for prophylaxis and/or therapy of a viral infection
  申请人：Harbins Ruhr Bioscience, Inc.

  公开号：US10688065B2

  公开（公告）日：2020-06-23

  Provided are processes for the prevention or treatment of viral infection in a subject. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the nose or interior of the nose or portion thereof, the ability of viruses to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.

  本文提供了预防或治疗受试者病毒感染的方法。某些方面提供了向人等受试者施用鞘氨醇化合物（可选鞘氨醇）、激活生成鞘氨醇基（可选鞘氨醇）的活性成分；或抑制鞘氨醇基（可选鞘氨醇）降解的活性剂。通过增加施用组合物的受试者或受试者的局部（如鼻子或鼻子内部或其部分）的鞘氨醇浓度，可降低病毒感染受试者或其细胞的能力，从而达到预防病毒感染的目的。
• Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection
  申请人：Harbins Ruhr Bioscience, Inc.

  公开号：US11298412B2

  公开（公告）日：2022-04-12

  Provided are processes for the prevention or treatment of infection by SARS-CoV-2. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the airways, nose or interior of the nose or portion thereof, the ability or SARS-CoV-2 to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.

  本文提供了预防或治疗 SARS-CoV-2 感染的方法。某些方面提供了对人等受试者施用鞘氨醇化合物（可选鞘氨醇）、激活鞘氨醇基（可选鞘氨醇）生成的活性成分；或抑制鞘氨醇基（可选鞘氨醇）降解的活性剂。通过增加受试者或受试者施用组合物的部位（如呼吸道、鼻腔或鼻腔内部或其部分）的鞘氨醇的局部浓度，可降低 SARS-CoV-2 感染受试者或其细胞的能力，从而起到预防病毒感染的作用。
• MUTANT ENDOGLYCOCERAMIDASES WITH ENHANCED SYNTHETIC ACTIVITY
  申请人：Seneb Biosciences, Inc.

  公开号：EP1765998B1

  公开（公告）日：2011-09-21
• Mutant Endoglycoceramidases With Enhanced Synthetic Activity
  申请人：Johnson Karl F.

  公开号：US20090170155A1

  公开（公告）日：2009-07-02

  The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.